Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs

J Intern Med. 1996 Oct;240(4):249-51. doi: 10.1046/j.1365-2796.1996.43869000.x.

Abstract

A 40-year-old woman with transplanted lungs developed life threatening hyperkalaemia (6.8 mmol L-1) during high dose treatment with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia. Trimethoprim has an amiloride-like effect on the distal nephron and may thus induce hyperkalaemia, particularly if other contributing factors coexist. The present patient was also treated with the angiotensin-converting enzyme (ACE) inhibitor enalapril, and the combination of ACE-inhibition and potassium-sparing diuretics is known to induce hyperkalaemia. Hyperkalaemia was probably induced by the combination of ACE-inhibitor and trimethoprim, and this combination may be as dangerous as the combination of ACE-inhibitors with other potassium-sparing diuretics.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Anti-Infective Agents / adverse effects*
  • Enalapril / adverse effects*
  • Fatal Outcome
  • Female
  • Humans
  • Hyperkalemia / chemically induced*
  • Lung Transplantation*
  • Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Anti-Infective Agents
  • Enalapril
  • Trimethoprim, Sulfamethoxazole Drug Combination